

Supplementary data

Table 3. More specific indications for primary THA (includes only patients operated in years 2014–2017). Values are count (%)

Diagnosis	DMC (Trident) n = 306	DMC (Others) n = 134	CL < 36 mm n = 185	CL 36 mm n = 203	Conventional THA n = 34,557
Osteoarthritis	188 (61)	50 (37)	62 (34)	53 (26)	29,218 (85)
Hip fracture	84 (27)	68 (51)	60 (32)	34 (17)	1,748 (5.1)
Avascular caput necrosis	17 (5.6)	6 (4.5)	8 (4.3)	4 (2.0)	953 (2.8)
Developmental dysplasia of the hip	2 (0.7)	—	3 (1.6)	3 (2.2)	503 (1.5)
Failed osteosynthesis after hip fracture	2 (0.7)	2 (1.5)	23 (12)	14 (6.9)	53 (0.2)
Secondary osteoarthritis after hip fracture	—	1 (0.7)	1 (0.5)	5 (2.5)	100 (0.3)
Inflammatory joint disease	3 (1.0)	3 (2.2)	—	—	550 (1.6)
Purulent arthritis	—	—	—	1 (0.5)	12 (0.03)
Childhood joint disease	—	—	—	—	108 (0.3)
Tumor	—	1 (0.7)	4 (2.2)	65 (32)	41 (0.1)
Other disease	1 (0.3)	—	10 (5.4)	8 (3.9)	169 (0.5)
Data missing	9 (2.9)	3 (2.2)	14 (7.6)	16 (7.9)	1,102 (3.2)

Table 5. Cumulative incidence function estimates at 1, 3, and 6 years of first revision and death with 95% confidence intervals for the CL < 36 mm group stratified by the femoral head size

	CL 22 mm n = 64	CL 28 mm n = 111	CL 32 mm n = 127
Risk of revision			
1 year	11 (3.2–19)	10 (4.3–16)	8.0 (3.2–13)
3 years	13 (4.4–21)	14 (6.8–20)	14 (7.1–21)
6 years	13 (4.4–21)	14 (6.8–20)	14 (7.1–21)
Risk of death			
1 year	9.4 (2.2–17)	6.5 (1.8–11)	9.1 (3.9–14)
3 years	27 (15–39)	17 (9.0–26)	17 (9.6–24)
6 years	42 (28–56)	31 (17–45)	37 (25–49)




Figure 3. Cumulative incidence function estimates of the first revision with death as competing event.